newsfilter
← Latest News
Business Wire·

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology

BANNOCKBURN, Ill. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, today announced a broad strategic immuno-oncology collaboration.